Evidence map›Paper›PMID 24945624›Full record

ArticlePLoS pathogens2014

The glycosylated Rv1860 protein of Mycobacterium tuberculosis inhibits dendritic cell mediated TH1 and TH17 polarization of T cells and abrogates protective immunity conferred by BCG.

Vijaya Satchidanandam, Naveen Kumar, Rajiv S Jumani, Vijay Challu, Shobha Elangovan, Naseem A Khan

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 28 citations in OpenAlex.

  1. Recent Characterization of Key Proteins to Combat Tuberculosis.Advances in experimental medicine and biology · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. cGAS/STING/TBK1/IRF3 Signaling Pathway Activates BMDCs Maturation FollowingInternational journal of molecular sciences · 2019
    Article
  6. FuFangChangTai Decoction Activates Macrophages via Inducing Autophagy.Evidence-based complementary and alternative medicine : eCAM · 2019
    Article
  7. Article
  8. Article
  9. Emerging facets of prokaryotic glycosylation.FEMS microbiology reviews · 2017
    Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Recombinant Lipoprotein Rv1016c Derived fromFrontiers in cellular and infection microbiology · 2016
    Article
  15. Article
  16. CHO expressed recombinant human lactoferrin as an adjuvant for BCG.International journal of immunopathology and pharmacology · 2015
    Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Vijaya SatchidanandamDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, Karnataka, India.
Naveen KumarDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, Karnataka, India.
Rajiv S JumaniDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, Karnataka, India.
Vijay ChalluNational Tuberculosis Institute, Bangalore, Karnataka, India.
Shobha ElangovanDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, Karnataka, India.
Naseem A KhanDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, Karnataka, India.
Indian Institute of Science Bangalore · INNational Tuberculosis Institute · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously reported interferon gamma secretion by human CD4⁺ and CD8⁺ T cells in response to recombinant E. coli-expressed Rv1860 protein of Mycobacterium tuberculosis (MTB) as well as protection of guinea pigs against a challenge with virulent MTB following prime-boost immunization with DNA vaccine and poxvirus expressing Rv1860. In contrast, a Statens Serum Institute Mycobacterium bovis BCG (BCG-SSI) recombinant expressing MTB Rv1860 (BCG-TB1860) showed loss of protective ability compared to the parent BCG strain expressing the control GFP protein (BCG-GFP). Since Rv1860 is a secreted mannosylated protein of MTB and BCG, we investigated the effect of BCG-TB1860 on innate immunity. Relative to BCG-GFP, BCG-TB1860 effected a significant near total reduction both in secretion of cytokines IL-2, IL-12p40, IL-12p70, TNF-α, IL-6 and IL-10, and up regulation of co-stimulatory molecules MHC-II, CD40, CD54, CD80 and CD86 by infected bone marrow derived dendritic cells (BMDC), while leaving secreted levels of TGF-β unchanged. These effects were mimicked by BCG-TB1860His which carried a 6-Histidine tag at the C-terminus of Rv1860, killed sonicated preparations of BCG-TB1860 and purified H37Rv-derived Rv1860 glycoprotein added to BCG-GFP, but not by E. coli-expressed recombinant Rv1860. Most importantly, BMDC exposed to BCG-TB1860 failed to polarize allogeneic as well as syngeneic T cells to secrete IFN-γ and IL-17 relative to BCG-GFP. Splenocytes from mice infected with BCG-SSI showed significantly less proliferation and secretion of IL-2, IFN-γ and IL-17, but secreted higher levels of IL-10 in response to in vitro restimulation with BCG-TB1860 compared to BCG-GFP. Spleens from mice infected with BCG-TB1860 also harboured significantly fewer DC expressing MHC-II, IL-12, IL-2 and TNF-α compared to mice infected with BCG-GFP. Glycoproteins of MTB, through their deleterious effects on DC may thus contribute to suppress the generation of a TH1- and TH17-dominated adaptive immune response that is vital for protection against tuberculosis.

Indexed as

Adaptive ImmunityImmunologic MemoryAnimalsBacterial ProteinsBCG VaccineCell PolarityCells, CulturedDendritic CellsFemaleGlycoproteinsGlycosylationInflammation MediatorsMacrophages, PeritonealMice, Inbred BALB CMycobacterium bovisMycobacterium tuberculosisBacterial ProteinsBCG VaccineGlycoproteinsInflammation MediatorsRecombinant Proteins

Identifiers

PMID24945624
PMCPMC4055742
OpenAlexW2058146053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.